Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity.
gastrointestinal tolerability
modified release
obesity
type‐2 diabetes
Journal
Obesity science & practice
ISSN: 2055-2238
Titre abrégé: Obes Sci Pract
Pays: United States
ID NLM: 101675151
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
21
10
2019
revised:
14
01
2020
accepted:
15
01
2020
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
12
6
2020
Statut:
epublish
Résumé
There is an unmet medical need for a safe and effective weight loss product with minimal systemic side-effects. In this study, the effect of a novel modified-release fixed-dose combination of orlistat and acarbose (MR-OA) was compared with conventional orlistat (CO) regarding tolerability, appetite and glucose metabolism. Sixty-seven men with obesity, aged 24 to 60 years with body mass indexes (BMIs) 33 to 40 kg m In the MR-OA groups, reports of liquid and oily stools as well as faecal incontinence were fewer, whereas reports of gastric distension and flatulence were higher, compared with the CO group. More participants reported decreased hunger in the 90/30 and 120/40 MR-OA, and postprandial plasma glucose concentration was reduced in all MR-OA groups compared with CO. This study shows that by using a modified-release dosage form, orlistat and acarbose can be combined without compromising tolerability. Furthermore, MR-OA shows promising effects regarding reduction of appetite and reduces postprandial glucose. Tolerability is coupled to compliance and thereby efficacy of a treatment; therefore, this novel combination MR-OA could be an effective approach for weight loss treatment. A follow-up study in a more diverse population and for a longer duration with weight loss as primary outcome variable is planned.
Identifiants
pubmed: 32523721
doi: 10.1002/osp4.405
pii: OSP4405
pmc: PMC7278902
doi:
Types de publication
Journal Article
Langues
eng
Pagination
313-323Informations de copyright
© 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare the following competing financial interests: Holmbäck U, Forslund A, Grudén S, Alderborn G, Söderhäll A and Lennernäs H have equity interests in Empros Pharma AB and have acted as consultants for the company. Söderhäll A is the CEO of Empros Pharma.
Références
Epidemiol Rev. 2014;36:71-82
pubmed: 24042431
Diabetologia. 2004 Dec;47(12):2208-14
pubmed: 15662558
Gut. 1996 Jun;38(6):916-9
pubmed: 8984033
Diabet Med. 1998 Jun;15(6):485-91
pubmed: 9632123
Obes Rev. 2001 Aug;2(3):141-7
pubmed: 12120099
Diabet Med. 1998 Feb;15(2):120-4
pubmed: 9507911
Clin Nutr. 2002 Oct;21(5):395-402
pubmed: 12381337
Appetite. 2014 Dec;83:153-9
pubmed: 25149199
Clin Chem. 2018 Jan;64(1):118-129
pubmed: 29054924
Diabetes Care. 2007 Jan;30(1):27-32
pubmed: 17192328
Diabetes Res Clin Pract. 2001 Jun;52(3):193-204
pubmed: 11323089
Obes Rev. 2017 Dec;18(12):1377-1385
pubmed: 29024559
Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G482-9
pubmed: 19109408
Appetite. 2014 Sep;80:236-41
pubmed: 24819342
Appetite. 2010 Dec;55(3):407-12
pubmed: 20670666
Eur J Clin Nutr. 2002 Aug;56(8):740-7
pubmed: 12122550
J Clin Endocrinol Metab. 2003 Aug;88(8):3829-34
pubmed: 12915676
Physiol Behav. 2013 Mar 15;112-113:84-9
pubmed: 23458628
Diabet Med. 2005 Apr;22(4):470-6
pubmed: 15787675
Lancet. 2002 Jun 15;359(9323):2072-7
pubmed: 12086760
Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886
pubmed: 28917545
World J Diabetes. 2011 Feb 15;2(2):19-23
pubmed: 21537456
Int J Obes Relat Metab Disord. 2001 Jul;25(7):1095-9
pubmed: 11443512
J Clin Endocrinol Metab. 2008 Oct;93(10):3995-8
pubmed: 18647814
Nutr Res Rev. 2015 Jun;28(1):1-21
pubmed: 25790334
Obes Rev. 2009 Sep;10(5):564-75
pubmed: 19460116
Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G752-63
pubmed: 11518688
Diabetes Care. 2004 Jan;27(1):155-61
pubmed: 14693982
Eur J Clin Pharmacol. 1998 Apr;54(2):125-32
pubmed: 9626916
Am J Clin Nutr. 1985 Mar;41(3):511-6
pubmed: 3883743
Br J Nutr. 2019 Oct 28;122(8):942-950
pubmed: 31182181
Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S307-9
pubmed: 24251196
Expert Opin Pharmacother. 2007 Aug;8(11):1733-42
pubmed: 17685889
Biochimie. 2014 Jun;101:221-31
pubmed: 24508576
Scand J Gastroenterol. 1995 Sep;30(9):892-6
pubmed: 8578189
Physiol Behav. 2008 Oct 20;95(3):271-81
pubmed: 18692080
J Intern Med. 2000 May;247(5):607-14
pubmed: 10810001
Appetite. 2014 Oct;81:116-22
pubmed: 24953196
Am J Physiol Regul Integr Comp Physiol. 2013 Dec;305(11):R1215-67
pubmed: 23904103
Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E948-53
pubmed: 15998659
Biochim Biophys Acta Mol Basis Dis. 2017 May;1863(5):1026-1036
pubmed: 28130199
Obes Rev. 2019 Jul;20(7):983-997
pubmed: 30945414
Obes Sci Pract. 2016 Jun;2(2):104-114
pubmed: 27840686
JAMA. 2016 Jun 14;315(22):2424-34
pubmed: 27299618
Neuroimage. 2014 Oct 15;100:405-13
pubmed: 24862077
Obes Rev. 2010 Mar;11(3):251-70
pubmed: 20122136
Colloids Surf B Biointerfaces. 2013 Nov 1;111:306-12
pubmed: 23838197
J Diabetes Complications. 2016 May-Jun;30(4):628-37
pubmed: 26935335
Clin Drug Investig. 2013 Apr;33(4):263-74
pubmed: 23435929
Int J Clin Pract. 2019 Nov;73(11):e13399
pubmed: 31397946
Int J Obes (Lond). 2014 May;38(5):689-97
pubmed: 23942319
Diabetes Obes Metab. 2016 Jun;18(6):558-70
pubmed: 26936802
Int J Clin Pract. 2014 Nov;68(11):1318-32
pubmed: 24853116
J Diabetes Sci Technol. 2011 Nov 01;5(6):1572-83
pubmed: 22226280
Curr Obes Rep. 2018 Jun;7(2):147-161
pubmed: 29504049